AGIOS PHARMACEUTICALS, INC. (AGIO)
About AGIOS PHARMACEUTICALS, INC.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $54.0M
- Net income
- -$412.8M
- Total assets
- $1.3B
- Market cap
- $1.7B
- Gross margin
- 88.3%
- Operating margin
- -873.9%
- Net margin
- -764.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $54.0M
- Cost of revenue
- $6.3M
- Gross profit
- $47.7M
- Operating expenses
- $519.8M
- Operating income
- -$472.1M
- Income tax
- -$1.0M
- Net income
- -$412.8M
- EPS (basic)
- $-7.12
- EPS (diluted)
- $-7.12
Balance sheet
- Total assets
- $1.3B
- Current assets
- $942.1M
- Total liabilities
- $104.1M
- Current liabilities
- $82.2M
- Shareholders’ equity
- $1.2B
Cash flow
- Operating cash flow
- -$373.0M
- Investing cash flow
- $377.2M
- Financing cash flow
- $8.7M
- Net cash flow
- $12.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.7B
- EPS (diluted)
- $-7.12
- Shares outstanding
- 42.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 24, 2013
Agios Pharmaceuticals, Inc. (AGIO) Stock Price
- Reported a net loss of $412.8M in FY2025.
- Gross margin of 88.3%, net margin -764.0%.
- Trading 13% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AGIOS PHARMACEUTICALS, INC..
Write a review
News about AGIOS PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
Agios Pharmaceuticals, Inc.: frequently asked questions
Is Agios Pharmaceuticals, Inc. an American company?
Agios Pharmaceuticals, Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Agios Pharmaceuticals, Inc. headquartered?
Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts, United States.
Is Agios Pharmaceuticals, Inc. publicly traded?
Yes — Agios Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol AGIO on the NASDAQ.
What does Agios Pharmaceuticals, Inc. do?
Agios Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
When was Agios Pharmaceuticals, Inc. founded?
Agios Pharmaceuticals, Inc. was founded in 2008.
